Bladder Cancer

Gene-mediated therapy for high-grade NMIBC delivers positive results in trial

July 14, 2020

72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.

Cabozantinib shows intriguing activity in heavily pretreated urothelial carcinoma

July 08, 2020

Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.

How to perform office-based blue light cystoscopy

July 07, 2020

BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

July 06, 2020

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

FDA approves avelumab as frontline maintenance in urothelial carcinoma

July 01, 2020

The FDA has approved the PD-L1 inhibitor avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors

June 22, 2020

The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.

Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer

June 19, 2020

Median overall survival is the same for both malignancies, study results show.

Biomarker combo forecasts improved survival with anti–PD-1/L1 agents in bladder cancer

June 18, 2020

The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.

Immune checkpoint inhibitors effective in variant urothelial carcinoma

June 17, 2020

Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.

FDA approves pembrolizumab across TMB-high solid tumors

June 17, 2020

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.